Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass., June 19, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the pricing...
-
CAMBRIDGE, Mass., June 18, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that it has...
-
Post-vaccination T cell responses detected to 91% of vaccine neoantigens, including CD8+ T cell responses to 53% of vaccine neoantigens Conference call and webcast to discuss results TODAY at 8:30...
-
Poster presentation tomorrow, June 1st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3rd at 8:30 am ET CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE)...
-
CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced a research...
-
Post-vaccination immune responses detected to 93% of vaccine neoantigens in first three patients analyzed Additional data to be presented June 1st at ASCO 2019 and discussed on a conference call and...
-
Company anticipates presenting first GEN-009 immunogenicity data at ASCO 2019 Conference call today at 9:00 am ET CAMBRIDGE, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc....
-
CAMBRIDGE, Mass., April 23, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, will host its first-quarter...
-
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced that Chip...
-
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing neoantigen cancer immunotherapies, today announced the...